Pathophysiological mechanism of non-HIV Pneumocystis jirovecii pneumonia
- PMID: 35501264
- DOI: 10.1016/j.resinv.2022.04.002
Pathophysiological mechanism of non-HIV Pneumocystis jirovecii pneumonia
Abstract
While Pneumocystis jirovecii pneumonia (PCP) can occur in immunocompromised patients with HIV infection, the prognosis of non-HIV PCP is still poor, showing a high mortality rate of 30%-75%. The pathophysiological mechanism of non-HIV PCP is quite different from that of HIV-PCP. Aging, underlying disease, dysbiotic gut microbiome, and Th1 predominance, leads to macrophagic polarization shifting from M2 to M1. These cause dysregulation in the host immunity against P. jirovecii, resulting in severe lung injury and a high mortality rate among non-HIV PCP patients. This review describes poor prognostic factors, an issue of predictive values used for general pneumonia practice, and new aspects, including the dysbiosis of the gut microbiome and macrophagic polarization in the treatment of non-HIV PCP.
Keywords: Human immunodeficiency virus; Macrophage polarization; Microbiome; Pneumocystis jirovecii pneumonia; Th1-predominance.
Copyright © 2022 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of Interest The authors declare that they have no conflict of interest.
Similar articles
-
A comprehensive clinical guide for Pneumocystis jirovecii pneumonia: a missing therapeutic target in HIV-uninfected patients.Expert Rev Respir Med. 2022 Nov-Dec;16(11-12):1167-1190. doi: 10.1080/17476348.2022.2152332. Epub 2022 Dec 12. Expert Rev Respir Med. 2022. PMID: 36440485 Review.
-
Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection.J Infect. 2014 Jul;69(1):88-95. doi: 10.1016/j.jinf.2014.02.015. Epub 2014 Mar 4. J Infect. 2014. PMID: 24607411
-
Clinical significance of positive Pneumocystis jirovecii polymerase chain reaction in non-human immunodeficiency virus immunocompromised patients in a real practice.Korean J Intern Med. 2017 May;32(3):478-485. doi: 10.3904/kjim.2015.340. Epub 2016 Dec 13. Korean J Intern Med. 2017. PMID: 27951623 Free PMC article.
-
Circulating and Pulmonary T-cell Populations Driving the Immune Response in Non-HIV Immunocompromised Patients with Pneumocystis jirovecii Pneumonia.Int J Med Sci. 2019 Aug 14;16(9):1221-1230. doi: 10.7150/ijms.34512. eCollection 2019. Int J Med Sci. 2019. PMID: 31588187 Free PMC article.
-
Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia.Respiration. 2018;96(1):52-65. doi: 10.1159/000487713. Epub 2018 Apr 10. Respiration. 2018. PMID: 29635251 Review.
Cited by
-
Pneumocystis Pneumonia Infection Following the Initiation of Pembrolizumab Therapy for Lung Adenocarcinoma.Intern Med. 2023 Nov 15;62(22):3381-3385. doi: 10.2169/internalmedicine.1163-22. Epub 2023 Mar 31. Intern Med. 2023. PMID: 37005268 Free PMC article.
-
Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis.Elife. 2024 Apr 12;12:RP87288. doi: 10.7554/eLife.87288. Elife. 2024. PMID: 38607373 Free PMC article.
-
Spatiotemporal Clusters and Trends of Pneumocystis Pneumonia in Korea.Korean J Parasitol. 2022 Oct;60(5):327-338. doi: 10.3347/kjp.2022.60.5.327. Epub 2022 Oct 21. Korean J Parasitol. 2022. PMID: 36320109 Free PMC article.
-
Late-Onset Granulomatous Pneumocystis jirovecii Pneumonia in A Renal Transplant Recipient: A Clinical Grand Round Conference Case in 2022.Infect Chemother. 2023 Sep;55(3):309-316. doi: 10.3947/ic.2023.0084. Infect Chemother. 2023. PMID: 37794576 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
